Britain's Mail on Sunday newspaper said, citing mounting
speculation, that GSK is preparing a bid for Canada's Aurinia. The
report is not true, a GSK spokesperson said in an email.
Aurinia shares jumped almost 27% on Oct. 22 when Bloomberg News
cited people familiar with the matter as saying that U.S. group
Bristol Myers Squibb Co had expressed interest in buying the
company.
The stock has been up almost 50% since the report, giving the
biotech firm a market value of about $4.2 billion.
[to top of second column] |
![](http://archives.lincolndailynews.com/2021/Nov/01/images/ads/current/farmers_bank_sda_FHI_2021.png) Aurinia's drug Lupkynis is
approved to treat a form of kidney inflammation
caused by autoimmune disease lupus and the
company is working on other treatments for
autoimmune and kidney diseases.
(Reporting by Ludwig Burger; Editing by Kirsten
Donovan)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |